REVERSE-HF will evaluate ultrafiltration therapy in comparison to IV diuretics to treat heart failure patients with fluid overload MINNEAPOLIS, Sept. 27, 2022 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE), a commercial-stage company focused on transforming the lives of people with fluid overload, today announced the activation of three additional sites […]

REVERSE-HF will evaluate ultrafiltration therapy in comparison to IV diuretics to treat heart failure patients with fluid overload MINNEAPOLIS, June 29, 2022 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE) today announced the first patient has been enrolled in the company’s pivotal REVERSE-HF (Ultrafiltration Versus IV Diuretics in Worsening Heart Failure) clinical study. REVERSE-HF will evaluate […]

The REVERSE-HF study will evaluate ultrafiltration therapy for heart failure patients suffering from fluid overload MINNEAPOLIS, March 15, 2022 (GLOBE NEWSWIRE) — Nuwellis, Inc. (Nasdaq: NUWE) today announced it has received independent Institutional Review Board (IRB) approval for the trial protocol of the company’s REVERSE-HF (Ultrafiltration Versus IV Diuretics in Worsening Heart Failure) clinical study […]